Edwards Lifesciences Q4 FY25 earnings call EW

Edwards' TAVR segment achieved strong growth in Q4 FY25, propelled by compelling long-term durability data from PARTNER III and PARTNER II, alongside the practice-changing EARLY TAVR trial. These clinical advancements are fostering a renewed focus on SAPIEN therapy and driving increased urgency for treating severe aortic stenosis patients. The company anticipates further tailwinds from European guideline changes and the potential for an updated US TAVR National Coverage Determination later in 2026, reinforcing TAVR as a durable growth engine.

The Transcatheter Mitral and Tricuspid Therapies (TMTT) product group demonstrated significant growth in Q4, with full-year sales exceeding half a billion dollars. This expansion is attributed to the global adoption of PASCAL and EVOQUE, alongside the recent FDA approval and initial scaling of SAPIEN M3 in the US and Europe. Upcoming introductions of next-generation PASCAL and PASCAL for US tricuspid patients in Q4 are expected to further advance treatment options and contribute to the segment's multi-year growth trajectory towards its 2030 revenue target.

The Surgical product group surpassed $1 billion in full-year sales for the first time, despite Q4 growth being impacted by distributor inventory adjustments in one country. The company projects mid-single-digit sales growth for Surgical in 2026, primarily driven by the continued adoption of its RESILIA therapies, which offer extended durability. Edwards is also expanding its therapeutic reach by planning a preliminary introduction of a new surgical Left Atrial Appendage Closure (LAAC) technology later this year, complementing its existing valvular procedures.

Edwards made substantial strategic investments in Q4 FY25, increasing SG&A spending to amplify patient access to therapy. These initiatives include educational programs for EARLY TAVR, reinforcing field resources for THV and TMTT, and a multi-year partnership with the American Heart Association focused on elevating heart valve disease awareness and improving diagnosis and treatment. This elevated spending reflects the company's commitment to leveraging clinical evidence to drive broader adoption and improve patient outcomes.

The company's capital allocation priorities remain consistent, emphasizing internal investments for growth, such as production capacity, and external investments through M&A focused on structural heart opportunities. Edwards continued its share repurchase program in 2025, buying back approximately $900 million, with a significant authorization remaining. Management reiterated its opportunistic approach to share repurchases while actively exploring bolt-on acquisitions to strengthen its competitive position.

Management highlighted the increasing importance of lifetime management considerations in TAVR, driven by strong clinical evidence demonstrating the benefits of earlier intervention. The focus is on selecting the right first procedure to ensure optimal options for potential future interventions, such as valve-in-valve procedures or coronary artery access. This paradigm shift, supported by long-term SAPIEN data, positions Edwards' platform uniquely for both acute and long-term patient care.

While acknowledging the significant patient population for moderate Aortic Stenosis (AS), Edwards is awaiting the results of the PROGRESS trial, to be presented at TCT, before providing detailed commentary. The company expressed confidence in the potential impact of SAPIEN 3 for these patients, emphasizing its reliance on robust scientific clinical studies. The rapid enrollment of the PROGRESS trial suggests strong interest in this patient segment, which is distinct from asymptomatic AS.